- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07227012
간암 중 하나인 간세포암증을 진단받은 성인 참가자들을 대상으로 수술로 제거하기에는 너무 진행되어 다른 부위로 전이되었을 수 있는 경우, 단독 치료 및 병용 치료로서 PF-08634404라는 연구용 의약품에 대해 알아보기 위한 연구
AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
- Be 18 years or older.
- Have locally advanced or metastatic HCC.
- Is not a candidate for complete surgical or loco-regional therapies.
- Have not received any whole-body treatment for HCC.
Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
연구 개요
상태
개입 / 치료
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Pfizer CT.gov Call Center
- 전화번호: 1-800-718-1021
- 이메일: ClinicalTrials.gov_Inquiries@pfizer.com
연구 장소
-
-
-
Taichung, 대만, 407
- 모병
- Taichung Veterans General Hospital
-
Tainan, 대만, 704
- 모병
- National Cheng Kung University Hospital
-
Taipei, 대만, 10002
- 모병
- National Taiwan University Hospital
-
Taipei, 대만, 112
- 모병
- Taipei Veterans General Hospital
-
-
-
-
California
-
Irvine, California, 미국, 92612
- 모병
- Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Irvine, California, 미국, 92612
- 모병
- UCI Health - Irvine Infusion Pharmacy ACC
-
Irvine, California, 미국, 92612
- 모병
- UCI Health - Irvine
-
Los Angeles, California, 미국, 90033
- 모병
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, 미국, 90033
- 모병
- Keck Hospital of USC
-
Los Angeles, California, 미국, 90033
- 모병
- USC/Norris Comprehensive Cancer Center / Investigational Drug Services
-
Los Angeles, California, 미국, 90033
- 모병
- Los Angeles General Medical Center
-
Los Angeles, California, 미국, 90025
- 모병
- START Los Angeles, LLC
-
Los Angeles, California, 미국, 90067
- 모병
- LACN Century City
-
Orange, California, 미국, 92868
- 모병
- UC Irvine Health - Chao Family Comprehensive Cancer Center
-
Pasadena, California, 미국, 91105
- 모병
- Keck Medical Center of USC Pasadena
-
-
Florida
-
Land O' Lakes, Florida, 미국, 34638
- 모병
- Moffitt Cancer Center at Speros
-
Ruskin, Florida, 미국, 33570
- 모병
- Moffitt Cancer Center at SouthShore
-
Tampa, Florida, 미국, 33612
- 모병
- Moffitt Cancer Center - McKinley Campus
-
Tampa, Florida, 미국, 33612
- 모병
- Moffitt Cancer Center
-
Tampa, Florida, 미국, 33612
- 모병
- Moffitt McKinley Hospital
-
Tampa, Florida, 미국, 33607
- 모병
- Moffitt Cancer Center - International Plaza
-
Wesley Chapel, Florida, 미국, 33544
- 모병
- Moffitt Cancer Center at Wesley Chapel
-
-
Illinois
-
Shiloh, Illinois, 미국, 62269
- 모병
- Siteman Cancer Center - Shiloh
-
Shiloh, Illinois, 미국, 62269
- 모병
- Memorial Hospital
-
-
Minnesota
-
Coon Rapids, Minnesota, 미국, 55433
- 모병
- Allina Health Cancer Institute - Mercy Hospital
-
Minneapolis, Minnesota, 미국, 55407
- 모병
- Allina Health Cancer Institute - Abbott Northwestern Hospital
-
Saint Paul, Minnesota, 미국, 55102
- 모병
- Allina Health Cancer Institute - United Hospital
-
-
Missouri
-
City of Saint Peters, Missouri, 미국, 63376
- 모병
- Siteman Cancer Center - St. Peters
-
Creve Coeur, Missouri, 미국, 63141
- 모병
- Siteman Cancer Center - West County
-
Florissant, Missouri, 미국, 63031
- 모병
- Siteman Cancer Center - North County
-
Kansas City, Missouri, 미국, 64111
- 모병
- Saint Luke's Hospital of Kansas City
-
Kansas City, Missouri, 미국, 64111
- 모병
- Saint Luke's Cancer Institute
-
St Louis, Missouri, 미국, 63108
- 모병
- Siteman Cancer Center
-
St Louis, Missouri, 미국, 63110
- 모병
- Washington University School of Medicine - Siteman Cancer Center
-
St Louis, Missouri, 미국, 63110
- 모병
- Barnes-Jewish Hospital
-
St Louis, Missouri, 미국, 63129
- 모병
- Siteman Cancer Center - South County
-
-
Nevada
-
Reno, Nevada, 미국, 89502
- 모병
- Renown Regional Medical Center
-
Reno, Nevada, 미국, 89502
- 모병
- Renown Health Medical Oncology
-
Reno, Nevada, 미국, 89502
- 모병
- Renown Office of Clinical Research
-
-
North Carolina
-
Cary, North Carolina, 미국, 27518
- 모병
- Duke Cancer Center Cary
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke Cancer Center
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University - Main Hospital and Clinics
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke Cancer Center - Investigational Chemotherapy Service
-
Raleigh, North Carolina, 미국, 27609
- 모병
- Duke Cancer Center Raleigh
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- 모병
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15212
- 모병
- AHN Allegheny General Hospital
-
Pittsburgh, Pennsylvania, 미국, 15212
- 모병
- AHN Cancer Institute at Allegheny General Hospital
-
-
Washington
-
Seattle, Washington, 미국, 98101
- 모병
- Virginia Mason Medical Center
-
Seattle, Washington, 미국, 98109
- 모병
- Fred Hutchinson Cancer Center
-
Seattle, Washington, 미국, 98195
- 모병
- University of Washington Medical Center- Montlake
-
-
-
-
-
Fukuoka, 일본, 811-1395
- 모병
- National Hospital Organization Kyushu Cancer Center
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 464-8681
- 모병
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa, Chiba, 일본, 277-8577
- 모병
- National Cancer Center Hospital East
-
-
Osaka
-
Sakai, Osaka, 일본, 590-0197
- 모병
- Kindai University Hospital- Osaka Medical Campus
-
-
Tokyo
-
Chuo-ku, Tokyo, 일본, 104-0045
- 모병
- National Cancer Center Hospital
-
-
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200032
- 모병
- Zhongshan Hospital,Fudan University
-
-
-
-
-
San Juan, 푸에르토 리코, 00909
- 모병
- Pan American Center for Oncology Trials, LLC
-
-
United States of America
-
Dorado, United States of America, 푸에르토 리코, 00646
- 모병
- Pan American Center for Oncology Trials, LLC - Dorado Office
-
Mayagüez, United States of America, 푸에르토 리코, 00680
- 모병
- Pan American Center for Oncology Trials, LLC - Mayaguez Office
-
Ponce, United States of America, 푸에르토 리코, 00730
- 모병
- Pan American Center for Oncology Trials, LLC - Ponce Office
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 18 years of age or older at screening.
- Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
- Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
- At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
- Adequate hepatic, liver, and renal function
- No prior systemic therapy for HCC.
- ECOG performance status 0 or 1
- Child-Pugh Class A
Key Exclusion Criteria:
- Moderate or severe ascites.
- History of hepatic encephalopathy.
- Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
- Clinically significant risk of hemorrhage or fistula.
- Participants with any history of another malignancy within 3 years.
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
- Clinically significant cardiovascular disease within 6 months prior to the first dose.
- Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
- History of severe bleeding tendency or coagulation dysfunction.
- History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
- Participants with acute, chronic or symptomatic infections.
- Participants with history of immunodeficiency.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Phase 1b
Participants will be allocated to sequential dose levels of PF-08634404 and ipilimumab. |
Solution for infusion Solution for infusion
다른 이름들:
|
|
실험적: Phase 2
Participants will be randomized to receive either PF-08634404 monotherapy or PF-08634404 combined with ipilimumab. |
Solution for infusion Solution for infusion
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants With Adverse Events
기간: Through end of study and up to approximately 24 months
|
Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through end of study and up to approximately 24 months
|
|
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
기간: Through 90 days after the last dose of study intervention; Approximately 24 months
|
DLTs are a predefined set of adverse events that are at least possibly related to any or all of the study interventions. The number of participants who experienced DLTs during the DLT observation period. |
Through 90 days after the last dose of study intervention; Approximately 24 months
|
|
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
기간: Approximately 24 months
|
ORR is the proportion of participants with a best overall response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
기간: Approximately 24 months
|
The doses of PF-08634404 and ipilimumab selected to be used in combination based on safety, tolerability, pharmacokinetics, and initial anti-tumor efficacy from Phase 2. |
Approximately 24 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 1b: Confirmed Objective Response Rate (ORR) using RECIST 1.1 as assessed by investigator
기간: Approximately 24 months
|
ORR is the proportion of participants with a best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Duration of Response (DOR) per RECIST 1.1 by investigator
기간: Approximately 24 months
|
DOR is the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Progression Free Survival (PFS) per RECIST 1.1 by investigator
기간: Approximately 24 months
|
PFS is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Overall Survival (OS)
기간: Approximately 24 months
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 24 months
|
|
Number of Participants With Clinical Laboratory Abnormalities
기간: Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing |
Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
|
Pharmacokinetics (PK): Serum concentrations of PF-08634404
기간: Up to 24 months
|
Predose and/or postdose concentrations of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
|
Incidence of antidrug antibody against PF-08634404
기간: Up to 24 months
|
To evaluate immunogenicity of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Pfizer CT.gov Call Center, Pfizer
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- C6461013
- 2025-523525-17-00 (씨티스)
- Symbiotic-GI-13 (기타 식별자: Pfizer)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .